Pitt Pharmacy professor Jan Beumer, PharmD, PhD, DABT, was awarded a new National Cancer Institute (NCI) contract for Preclinical Drug Development Research. Beumer is a faculty member in our Department of Pharmaceutical Sciences.
The NCI contract is one of only three awarded in the nation. Beumer’s research will support the development of new cancer medications and he’ll conduct preclinical pharmacology research to support preclinical and clinical trials to define the most effective means of drug delivery. This NCI award makes his group eligible for up to $9.9 million in task orders over five years.
In addition to the NCI award, Beumer was selected for two other awards recently — the Michaele Christian Oncology Drug Development Award and Lectureship and the Merrill J. Egorin Excellence in Scientific Leadership Award. The first is intended to honor the contribution of individuals, particularly those in mid-career, to the development of novel agents for cancer therapy. The award consists of a plaque and a lectureship, delivered at the annual fall NCI Cancer Therapy Evaluation Program Early Drug Development meeting. The latter honors a UPMC Hillman Cancer Center Research faculty member that displays biomedical expertise, scientific passion and scholarly dedication. Egorin focused his laboratory investigations on preclinical and clinical pharmacology studies designed to improve development and use of anticancer agents. He was recognized nationally and internationally as a leader in the field of pharmacokinetics. This award honors his dedication as a clinician, scientist and educator.
Beumer is a professor in the Department of Pharmaceutical Sciences at the University of Pittsburgh School of Pharmacy.
